Compare Stocks: OCGN, MRNA, PFE, and ABCL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$5.71 +0.4%	$6.15	$2.74 ▼ $8.44	$1.74B	1.14	5.24 million shs	4.99 million shs
MRNA Moderna	$54.82 -5.4%	$59.37	$22.28 ▼ $85.60	$21.75B	0.94	5.79 million shs	7.76 million shs
OCGN Ocugen	$1.23 -2.4%	$1.35	$0.93 ▼ $2.73	$416.38M	2.18	4.66 million shs	4.08 million shs
PFE Pfizer	$25.10 +0.8%	$25.04	$23.11 ▼ $28.75	$142.54B	0.35	37.18 million shs	45.05 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+7.53%	-29.59%	+28.89%	+24.95%
MRNA Moderna	0.00%	+1.39%	-31.27%	+20.83%	+70.51%
OCGN Ocugen	0.00%	+1.65%	-18.54%	-31.67%	+14.95%
PFE Pfizer	0.00%	+2.34%	+3.33%	-4.73%	+5.33%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$5.71 +0.4%	$6.15	$2.74 ▼ $8.44	$1.74B	1.14	5.24 million shs	4.99 million shs
MRNA Moderna	$54.82 -5.4%	$59.37	$22.28 ▼ $85.60	$21.75B	0.94	5.79 million shs	7.76 million shs
OCGN Ocugen	$1.23 -2.4%	$1.35	$0.93 ▼ $2.73	$416.38M	2.18	4.66 million shs	4.08 million shs
PFE Pfizer	$25.10 +0.8%	$25.04	$23.11 ▼ $28.75	$142.54B	0.35	37.18 million shs	45.05 million shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+7.53%	-29.59%	+28.89%	+24.95%
MRNA Moderna	0.00%	+1.39%	-31.27%	+20.83%	+70.51%
OCGN Ocugen	0.00%	+1.65%	-18.54%	-31.67%	+14.95%
PFE Pfizer	0.00%	+2.34%	+3.33%	-4.73%	+5.33%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.67	Moderate Buy	$8.00	40.11% Upside
MRNA Moderna	1.82	Reduce	$40.00	-27.03% Downside
OCGN Ocugen	2.60	Moderate Buy	$9.50	672.36% Upside
PFE Pfizer	2.19	Hold	$28.50	13.55% Upside

Current Analyst Ratings Breakdown

Latest OCGN, MRNA, PFE, and ABCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/21/2026	MRNA Moderna	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$49.00 ➝ $67.00
7/20/2026	MRNA Moderna	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Underperform	$25.00
7/17/2026	ABCL AbCellera Biologics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	PFE Pfizer	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$34.00 ➝ $30.00
7/13/2026	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$36.00 ➝ $35.00
7/10/2026	PFE Pfizer	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$27.00 ➝ $26.00
7/8/2026	MRNA Moderna	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$33.00 ➝ $39.00
7/8/2026	PFE Pfizer	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$30.00 ➝ $28.00
7/7/2026	MRNA Moderna	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Sector Perform	$38.00 ➝ $45.00
7/7/2026	ABCL AbCellera Biologics	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Buy	$11.00
7/7/2026	MRNA Moderna	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underperform	$34.00 ➝ $38.00

(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	23.21	N/A	N/A	$3.23 per share	1.77
MRNA Moderna	$1.94B	11.19	N/A	N/A	$22.14 per share	2.48
OCGN Ocugen	$4.41M	94.42	N/A	N/A	($0.04) per share	-30.75
PFE Pfizer	$62.58B	2.29	$4.41 per share	5.69	$15.26 per share	1.64

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.48	N/A	N/A	N/A	-181.75%	-14.86%	-10.62%	8/5/2026 (Confirmed)
MRNA Moderna	-$2.82B	-$8.15	N/A	N/A	N/A	-143.55%	-26.64%	-19.32%	N/A
OCGN Ocugen	-$67.85M	-$0.24	N/A	N/A	N/A	N/A	-127,987.80%	-135.48%	8/6/2026 (Estimated)
PFE Pfizer	$7.77B	$1.31	19.16	8.81	N/A	11.83%	19.44%	8.41%	8/4/2026 (Estimated)

Latest OCGN, MRNA, PFE, and ABCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	OCGN Ocugen	-$0.05	N/A	N/A	N/A	$0.98 million	N/A
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1443	N/A	N/A	N/A	$7.85 million	N/A
8/4/2026	Q2 2026	PFE Pfizer	$0.68	N/A	N/A	N/A	$14.40 billion	N/A
7/31/2026	Q2 2026	MRNA Moderna	-$2.03	-$1.97	+$0.06	-$1.97	$102.93 million	$145.00 million
5/11/2026	Q1 2026	ABCL AbCellera Biologics	-$0.22	-$0.14	+$0.08	-$0.14	$5.41 million	$8.32 million
5/5/2026	Q1 2026	OCGN Ocugen	-$0.05	-$0.06	-$0.01	-$0.06	$0.42 million	$1.53 million
5/5/2026	Q1 2026	PFE Pfizer	$0.7220	$0.75	+$0.0280	$0.47	$13.84 billion	$14.45 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.85%	-13.20%	131.30%	16 Years

Latest OCGN, MRNA, PFE, and ABCL Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/24/2026	PFE Pfizer	quarterly	$0.43	7.01%	7/24/2026	7/24/2026	9/1/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	14.05	14.05
MRNA Moderna	0.08	2.41	2.35
OCGN Ocugen	4.17	1.86	1.86
PFE Pfizer	0.67	1.25	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
MRNA Moderna	75.33%
OCGN Ocugen	10.27%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
MRNA Moderna	10.80%
OCGN Ocugen	3.95%
PFE Pfizer	0.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	305.38 million	218.65 million	Optionable
MRNA Moderna	4,700	396.79 million	353.93 million	Optionable
OCGN Ocugen	80	338.52 million	325.15 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable

OCGN, MRNA, PFE, and ABCL Headlines

Recent News About These Companies

Glenmede Trust Co. NA Has $25.33 Million Position in Pfizer Inc. $PFE

20 minutes ago | marketbeat.com

First Nebraska Trust Co Acquires New Shares in Pfizer Inc. $PFE

2 hours ago | marketbeat.com

Pfizer (PFE) to Post Earnings on Tuesday

2 hours ago | americanbankingnews.com

Pfizer’s Quiet Pipeline Push Could Ignite PFE Rally

August 1 at 11:10 AM | tipranks.com

Janus Henderson Group PLC Has $90.51 Million Holdings in Pfizer Inc. $PFE

August 1 at 6:08 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of "Hold" from Brokerages

August 1 at 2:28 AM | americanbankingnews.com

Pfizer Inc. (NYSE:PFE) Receives Average Rating of "Hold" from Analysts

August 1 at 2:28 AM | marketbeat.com

Wall Street Zen Upgrades Pfizer (NYSE:PFE) to "Buy"

August 1 at 1:37 AM | americanbankingnews.com

Pfizer (NYSE:PFE) Upgraded by Wall Street Zen to Buy Rating

August 1 at 1:35 AM | marketbeat.com

Pfizer (PFE) Stock Looks Reasonable Based On Today’s Broader Checks

July 31 at 12:41 AM | finance.yahoo.com

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

July 31 at 7:41 PM | fool.com

Pfizer Yields 6.8%, Trades at 8.5X Earnings, and Has a Promising Late-Stage Weight Loss Drug. Why Are So Many Investors Still Ignoring the Stock?

July 31 at 3:30 PM | fool.com

Amgen Q2 Earnings Preview: Will the Beat Streak Continue?

July 31 at 2:40 PM | finance.yahoo.com

Pfizer's Bear Case Is Breaking

July 31 at 11:13 AM | seekingalpha.com

Pfizer: Still Mispriced By Mr. Market (Earnings Preview)

July 31 at 10:11 AM | seekingalpha.com

Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock

July 31 at 10:01 AM | zacks.com

Pfizer’s Litfulo meets Phase III goals in vitiligo, supporting regulatory filings

July 31 at 9:34 AM | thepharmaletter.comT

Vestor Capital LLC Acquires 680,445 Shares of Pfizer Inc. $PFE

July 31 at 6:25 AM | marketbeat.com

Norris Financial Group LLC Makes New Investment in Pfizer Inc. $PFE

July 31 at 6:02 AM | marketbeat.com

Orographic Financial Advisors LLC Takes Position in Pfizer Inc. $PFE

July 31 at 5:52 AM | marketbeat.com

Pfizer (NYSE:PFE) Faces a Crucial Pipeline Test

July 31 at 4:33 AM | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

OCGN, MRNA, PFE, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$5.71 +0.02 (+0.35%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$5.74 +0.03 (+0.51%)

As of 07/31/2026 07:57 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Moderna NASDAQ:MRNA

$54.82 -3.10 (-5.35%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$54.66 -0.16 (-0.29%)

As of 07/31/2026 07:57 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Ocugen NASDAQ:OCGN

$1.23 -0.03 (-2.38%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$1.24 +0.01 (+0.41%)

As of 07/31/2026 07:49 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Pfizer NYSE:PFE

$25.10 +0.19 (+0.76%)

Closing price 07/31/2026 03:59 PM Eastern

Extended Trading

$25.04 -0.07 (-0.26%)

As of 07/31/2026 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCGN, MRNA, PFE, and ABCL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCGN, MRNA, PFE, and ABCL Earnings

Compare Dividends

Latest OCGN, MRNA, PFE, and ABCL Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCGN, MRNA, PFE, and ABCL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

OCGN, MRNA, PFE, and ABCL Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Moderna NASDAQ:MRNA

Ocugen NASDAQ:OCGN

Pfizer NYSE:PFE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools